Table 2. Histopathology and TTP Year .... | American Society of Hematology

Table 2.

Histopathology and TTP

Year	CLL without transformation (mo)	Transformed	Total
<1	PD3 (5.6)	PD1 (0.4 mo, suspected Richter transformation)	4
		PD2 (1.1 mo, EBV⁺ HL)
		PD4 (8.4 mo, DLBCL)
1 to <2	PD7 (23.8)	PD5 (14.7 mo, HL/CLL)	3
1 to <2	PD7 (23.8)	PD6 (15.2 mo, DLBCL)	3
2 to <3	PD8 (27.9)		2
2 to <3	PD9 (33.9)		2
≥3	PD10 (36.9)		6
	PD11 (38.4)
	PD12 (38.8)
	PD13 (38.9)
	PD14 (42.8)
	PD15 (47.4)
Total	10	5	15

Year	CLL without transformation (mo)	Transformed	Total
<1	PD3 (5.6)	PD1 (0.4 mo, suspected Richter transformation)	4
		PD2 (1.1 mo, EBV⁺ HL)
		PD4 (8.4 mo, DLBCL)
1 to <2	PD7 (23.8)	PD5 (14.7 mo, HL/CLL)	3
1 to <2	PD7 (23.8)	PD6 (15.2 mo, DLBCL)	3
2 to <3	PD8 (27.9)		2
2 to <3	PD9 (33.9)		2
≥3	PD10 (36.9)		6
	PD11 (38.4)
	PD12 (38.8)
	PD13 (38.9)
	PD14 (42.8)
	PD15 (47.4)
Total	10	5	15

Patient identifier (TTP, histology if transformed).

DLBCL, diffuse large B-cell lymphoma; EBV⁺ HL, EBV⁺ Hodgkin lymphoma; HL/CLL, Hodgkin-like cells mixed with CLL.